HONG KONG, February 4 /PRNewswire/ --

- Maximizing Shareholder Interests Optimizing Future Development

One of the leading game developers and operators in the PRC, NetDragon Websoft Inc. ("NetDragon" or the "Company", with its subsidiary collectively the "Group"; Stock Code: 8288.HK) is pleased to announce that it has bought back 271,000 of its shares on 31 January 2008.

The total number of shares bought back up to 31 January 2008 now amounts to 4,276,000 shares, and the total amount paid is about HK$56,493,900 at prices of between HK$12.40 and HK$14.48 per share.

DÜSSELDORF, Germany, February 4 /PRNewswire/ --

- Sales up by 48% at EUR958 Million - EBITDA Margin Reaches High Level of 19%

- Another Acquisition in the Target Segment of Pharmaceutical Plastics in South America: Brazilian Market Leader for Pharma Plastic Taken Over

According to provisional figures, Gerresheimer AG has just completed another record year. In 2007 the company achieved sales of EUR957.7m, up by 48.1%; the adjusted Group EBITDA margin reached 19%. "This gratifying development completely and fully confirms our strategy," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG: "With the help of acquisitions we have successfully expanded our global presence and set the course for further growth."

DÜSSELDORF, Germany, February 4 /PRNewswire/ --

- Sales up by 48% at EUR958 Million - EBITDA Margin Reaches High Level of 19%

- Another Acquisition in the Target Segment of Pharmaceutical Plastics in South America: Brazilian Market Leader for Pharma Plastic Taken Over

According to provisional figures, Gerresheimer AG has just completed another record year. In 2007 the company achieved sales of EUR957.7m, up by 48.1%; the adjusted Group EBITDA margin reached 19%. "This gratifying development completely and fully confirms our strategy," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG: "With the help of acquisitions we have successfully expanded our global presence and set the course for further growth."

BORDEAUX-MÉRIGNAC, France, February 4 /PRNewswire/ --

- NAVIGATOR DVB-SH the First Such Equipment Available on the Market

VEENENDAAL, The Netherlands, February 4 /PRNewswire/ -- Nucletron BV and clinicians at The Cancer Centre, Northern Ireland, proudly report the first IMRT clinical treatment within the Conventional or Hypofractionated High-Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) clinical trial utilizing Nucletron's Oncentra(R) MasterPlan. CHHiP, part of the NCRN/NCRI portfolio of cancer trials and sponsored by the Institute of Cancer Research, is a Phase III national, multi-centre, randomized trial for the treatment of prostate cancer using external beam radiotherapy.

DUSSELDORF, Germany, February 4 /PRNewswire/ -- According to provisional figures, Gerresheimer AG has just completed another record year. In 2007 the company achieved sales of EUR957.7m, up by 48.1%; the adjusted Group EBITDA margin reached 19%. "This gratifying development completely and fully confirms our strategy," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG: "With the help of acquisitions we have successfully expanded our global presence and set the course for further growth."

Rapid expansion of operations in the South American pharma and life science market